Coherus Oncology Inc. Common Stock (CHRS)
Stock · NASDAQ · Health Care
$0.99as of 10/16/2026
Price chart
Active signals
CHRS Signal Track Record
How signals performed across all stocks →What CHRS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -2.4% | 49% | October 6, 2026 |
| Bollinger Band Breakdown | 22 | -7.7% | 32% | October 6, 2026 |
| Bollinger Band Breakout | 19 | +5.5% | 58% | July 6, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -15.9% | 22% | July 9, 2026 |
| Any 20-session window (baseline) | -5.0% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoc…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 144
- Website
- www.coherus.com/
Fundamentals
- 1-day range
- $0.974$1.07
- Market cap
- $195.13M
- P/E (trailing)
- —
- P/E (forward)
- -1.70
- EPS (trailing)
- $-1.03
- Dividend yield
- —
- Beta
- 0.98
- Avg. volume
- 1.15M
How Coherus Oncology Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Coherus Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
- PLXProtalix BioTherapeutics Inc. (DE) Common Stock$2.62▼ 2.96%Market cap $196.59MP/E 11.27$1.6$3.19
- DTILPrecision BioSciences Inc. Common Stock$5.77▼ 6.48%Market cap $191.45MP/E —$3.53$9.62
- VYGRVoyager Therapeutics Inc. Common Stock$1.9▼ 7.77%Market cap $189.12MP/E —$2.33$5.55
- ALECAlector Inc. Common Stock$1.84▼ 3.66%Market cap $203.18MP/E —$1.09$3.4
- OTLKOutlook Therapeutics Inc. Common Stock$0.488▼ 2.40%Market cap $181.85MP/E —$0.1611$2.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
| PLX Protalix BioTherapeutics Inc. (DE) Common Stock | $196.59M | 11.27 | $2.62 | ▼ 2.96% | $1.6$3.19 |
| DTIL Precision BioSciences Inc. Common Stock | $191.45M | — | $5.77 | ▼ 6.48% | $3.53$9.62 |
| VYGR Voyager Therapeutics Inc. Common Stock | $189.12M | — | $1.9 | ▼ 7.77% | $2.33$5.55 |
| ALEC Alector Inc. Common Stock | $203.18M | — | $1.84 | ▼ 3.66% | $1.09$3.4 |
| OTLK Outlook Therapeutics Inc. Common Stock | $181.85M | — | $0.488 | ▼ 2.40% | $0.1611$2.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Ali J. Satvat · June 5, 2026 · Grant60.0K
- Ali J. Satvat · June 5, 2026 · Grant30.0K
- Rita A. Karachun · June 5, 2026 · Grant60.0K
- Rita A. Karachun · June 5, 2026 · Grant30.0K
- Lee Nisley Newcomer · June 5, 2026 · Grant60.0K
- Lee Nisley Newcomer · June 5, 2026 · Grant30.0K
- Michael Lee Ryan · June 5, 2026 · Grant60.0K
- Michael Lee Ryan · June 5, 2026 · Grant30.0K
- Jill O'Donnell-Tormey · June 5, 2026 · Grant60.0K
- Jill O'Donnell-Tormey · June 5, 2026 · Grant30.0K
- Charles W. Newton · June 5, 2026 · Grant60.0K
- Charles W. Newton · June 5, 2026 · Grant30.0K
- Mats Wahlstrom · June 5, 2026 · Grant60.0K
- Mats Wahlstrom · June 5, 2026 · Grant30.0K
- Dennis M. Lanfear · May 29, 2026 · Grant125.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 57.77M
- Total value held
- $93.22M
- Institutional holders
- 152
- Unknown10.37M
- Unknown5.45M
- Unknown3.43M
- Unknown3.12M
- Unknown3.04M
- Unknown2.33M
- Unknown2.30M
- Unknown2.25M
- Unknown2.10M
- Unknown1.93M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets
Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.